Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $9.37
Previous CloseN/A
Volume95.69K
Average Volume (3M)570.28K
Market Cap
$64.81M
Enterprise Value$77.06M
Total Cash (Recent Filing)$88.70M
Total Debt (Recent Filing)$56.95M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Oct 29, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding40,257,526
10 Day Avg. Volume1,001,504
30 Day Avg. Volume570,282
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit1.20
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$4.78Price Target Upside196.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial StabilityOver $100M of cash provides a robust runway, with a $30M burn in 2024, indicating strong financial stability.
Growth StrategyThe 'acquire, test, treat' strategy, including initiatives to increase funnel interest and reduce patient fallout, is expected to drive growth acceleration.
Revenue GrowthThe company's revenue from outside the US exceeded expectations, showing strong traction and momentum.
Bears Say
Financial ConcernsThere is a worry that Pulmonx Corporation may need to secure financing in the next year or two that is unfavorable to equity holders.
Revenue ChallengesManagement lowered full-year revenue guidance due to a lower U.S. volume outlook, reflecting a substantial slowdown in growth.
Tariff ImpactTariffs could impact the business through component sourcing cost inflation and other countries' reciprocal tariffs, potentially harming gross margins.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.59 and its highest was $9.37 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $64.81M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Oct 29, 2025 which is in 84 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Jul 30, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.394 by $0.014.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.42.
How many shares outstanding does Pulmonx have?
Pulmonx has 40,257,526 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.394. Following the earnings report the stock price went down -41.587%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.78 (196.89% Upside)
$4.78 (196.89% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 256.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $64.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.19%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
-14.74%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, trading under the ticker symbol LUNG, is a medical technology company focused on developing and commercializing minimally invasive treatments for patients with chronic obstructive pulmonary disease (COPD) and other severe lung conditions. The company's flagship product is the Zephyr Endobronchial Valve, a device designed to improve lung function, exercise capacity, and quality of life for patients with emphysema, a form of COPD. Pulmonx operates primarily within the healthcare and medical device sectors, aiming to address significant unmet medical needs in respiratory care.
LUNG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Pulmonx showed strong international performance and promising initiatives like direct-to-patient campaigns and AI screening tools. However, the need to revise revenue guidance due to slower U.S. growth and challenges in converting new commercial initiatives offset these achievements.Read More>LUNG Stock 12 Month Forecast
Average Price Target
$4.78
▲(196.89%Upside)
Technical Analysis
Ownership Overview
7.02% Insiders
33.35% Mutual Funds
<0.01% Other Institutional Investors
42.76% Public Companies and
Individual Investors